HCC Liver-Link Study for Liver Cancer
Part of Cancer clinical trials.
This trial tests a program to help people with liver cancer get connected to care. It is for patients with specific tumor sizes and numbers, who may face barriers to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver tumors that fit certain size and number limits (e.g., one tumor 5-8 cm, or up to five tumors all under 3 cm).
- You are between 18 and 75 years old.
- You have had no more than two visits with a liver cancer doctor.
- You can read, write, and speak English.
- You are either Black, insured by Medicaid, live in a socially vulnerable area, or are not married.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This study looks at why some people with liver cancer are diagnosed at a later stage. Researchers want to understand differences in care and outcomes for patients in certain areas of Los Angeles County.
This study aims to improve care and access to treatment for people with liver cancer (HCC) who are uninsured or on Medicaid. If you qualify, you may receive assistance and support to ensure you can get the cancer treatment you need.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This study aims to improve how patients with liver cancer (hepatocellular carcinoma) get the support and information they need. Researchers will interview patients, caregivers, and healthcare providers to find better ways to navigate care.
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
Hear when a new Racial Disparities trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.